Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Type 2 Diabetes Mellitus (T2DM), Beta Ce...
Phase Not Applicable
Enrollment 296
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

* Research objectives: Evaluate and compare the clinical and paraclinical characteristics, complications, as well as the changes in beta cell function and HbA1C levels between two patient groups over a one-year follow-up period. +Research design: This is a prospective cohort study, monitoring patients at 3, 6, 9, and 12 months. * Study Population and Sample Size: The study is planned to be conducted on 296 Vietnamese patients (accounting for a 20% dropout rate) who are being examined at the University of Medicine and Pharmacy Hospital in Ho Chi Minh City. * Key Evaluation Indicators: The function of beta cells and insulin resistance status are measured through the indices of HOMA-B, HOMA-IR, fasting C-peptide levels, and HbA1C levels. * Time and location: The study will be conducted from February 2025 to February 2028 at the Endocrinology Clinic, University Medical Center Ho Chi Minh City.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Monitor and observe the clinical progression and beta cell function — Monitor and observe the clinical progression and beta cell function

Primary Outcomes

  • Changes in fasting blood C-peptide concentration (At baseline (T0), 6 months (T6), and 12 months (T12))
  • Beta Cell Function Index (HOMA-B) (At baseline (T0), 6 months (T6), and 12 months (T12))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-02-24
Completion: 2028-02
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 296 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Medical Center Ho Chi Minh City (UMC)
Principal Investigators:
  • Chi Khanh Hoang, Specialist physician level 1 (PRINCIPAL_INVESTIGATOR) - University of Medicine and Pharmacy of Ho Chi Minh City
  • Nam Quang Tran, Associate professor - Doctorat (STUDY_DIRECTOR) - University of Medicine and Pharmacy of Ho Chi Minh City
  • Tran Viet Thang, Doctorate (STUDY_DIRECTOR) - University of Medicine and Pharmacy of Ho Chi Minh City
Contact Information
Study Contact:
Chi Khanh Hoang, Specialist physician level 1
84985578494
chi.hk@umc.edu.vn
Interventions
  • Other: Monitor and observe the clinical progression and beta cell function — Monitor and observe the clinical progression and beta cell function
Study Locations (1 sites)
University of Medicine and Pharmacy of Ho Chi Minh City, Ho Chi Minh City, Cho Lon Ward 72700 Vietnam
Eligibility Criteria
Inclusion Criteria: * The patient is diagnosed with Type 2 Diabetes Mellitus according to the ADA 2024 criteria (Fasting Glucose ≥ 126 mg/dl, or Glucose after 2 hours of an Oral Glucose Tolerance Test ≥ 200 mg/dl, or HbA1C ≥ 6.5%, or with typical symptoms accompanied by any Glucose ≥ 200 mg/dl). * The duration of Type 2 Diabetes Mellitus does not exceed 10 years. * Classification by age of onset: Early onset group (\< 40 years) and typical onset group (≥ 40 years). * At least 6 months without the need for insulin and no recorded episodes of diabetic ketoacidosis since the time of diagnosis. * For the early-onset group: Autoantibodies (Anti-GAD, ICA) are negative and fasting C-peptide levels are \> 0.6 nmol/L. * The patient consents to participate in the study and signs the informed consent document. Exclusion Criteria: * Pregnant women or patients with acute illnesses at the time of assessment. * The patient has been diagnosed with or exhibits characteristics suggestive of Type 1 Diabetes Mellitus (such as a history of ketoacidosis, C-peptide \< 0.2 nmol/L). * Secondary diabetes mellitus due to pancreatic disorders (pancreatitis, pancreatic tumors, pancreatic resection), due to medications (glucocorticoids), or due to other endocrine disorders (Cushing's syndrome, hyperthyroidism, acromegaly). * Severe renal failure with an estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m². * Use of medications that affect beta cell function or complications such as prolonged high-dose corticosteroids, immunosuppressive agents, or chemotherapy. * Not of Vietnamese ethnicity. * Non-compliance with treatment guidelines or failure to attend scheduled follow-up appointments.
Conditions Pulmonary Hypertension Due to Lung Disea...
Phase Not Applicable
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Chronic lung diseases such as pulmonary fibrosis and chronic obstructive pulmonary disease (COPD) can lead to pulmonary hypertension. This serious complication involves increased pressure in the lung vessels, which strains the heart and worsens outcomes. Since the early symptoms are unclear, diagnosis often occurs too late, underscoring the need for simple, noninvasive methods of early detection. A key driver of the disease is vascular remodeling, which involves the narrowing and stiffening of blood vessels. This process involves changes in the extracellular matrix, particularly in the understudied basement membrane. Our project examines how specific components, especially non-classical collagens, change during disease progression. As vessels remodel, detectable fragments enter the bloodstream, potentially creating a molecular fingerprint of the disease. By analyzing lung tissue and blood samples, the investigators aim to identify non-invasive biomarkers for earlier diagnosis, better patient classification, and more personalized treatment.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Analysis of collagen fragments (within 48 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-07-01
Completion: 2030-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical University of Graz
Collaborators: Medical University of Vienna
Principal Investigators:
  • Nikolaus Kneidinger, MD (STUDY_CHAIR) - Medical University of Graz
Contact Information
Study Contact:
Grazyna Kwapiszewska-Marsh, PhD
004331638572918
grazyna.kwapiszewska-marsh@medunigraz.at
Johannes Lorenz Berg, PhD
004331638572917
johannes.berg@medunigraz.at
Nikolaus Kneidinger, MD
004331638513305
nikolaus.kneidinger@medunigraz.at
Medical University of Graz
Interventions
N/A
Study Locations (1 sites)
Medical University of Graz, Graz, Styria 8010 Austria
Eligibility Criteria
Inclusion criteria: Patients undergoing lung transplantation with COPD or PF, with or without associated PH and PAH. \- Outpatient cohort with COPD or PF, with or without associated PH or PAH. Exclusion criteria: * Presence of other lung diseases * Signs of infection, such as pneumonia, pulmonary tuberculosis, or pleural effusions.
Conditions Pulmonary Arterial Hypertension PAH
Phase PHASE1, PHASE2
Enrollment 120
Locations 29 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a Phase Ib/IIa clinical study of IMC-003 treatment in pulmonary arterial hypertension (PAH) patients receiving background therapy

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: IMC-003 and PAH background therapy — Subjects will receive 8 injections of IMC-003 and will also need to have stable background treatment for pulmonary arterial hypertension.
  • Drug: IMC-003 placebo and PAH background therapy — Subjects will receive 8 injections placebo of IMC-003 and will also need to have stable background treatment for pulmonary arterial hypertension.

Primary Outcomes

  • Phase Ib (24 weeks)
  • Phase IIa (24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2026-04-30
Completion: 2027-11-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
Principal Investigators:
  • Zhicheng Jing, M.D. (PRINCIPAL_INVESTIGATOR) - Guangdong Provincial People's Hospital
Contact Information
Study Contact:
Xiaojun Zhou
021-58356573
xiaojun.zhou@immunecarebio.com
Xiqi Xu
86+15300131702
15300131702@163.com
Xuanwu Hospital Capital Medical University
Hong Zhang
86+18186870853
jhongzhang@foxmail.com
The first hospital of Jilin University
Interventions
  • Drug: IMC-003 and PAH background therapy — Subjects will receive 8 injections of IMC-003 and will also need to have stable background treatment for pulmonary arterial hypertension.
  • Drug: IMC-003 placebo and PAH background therapy — Subjects will receive 8 injections placebo of IMC-003 and will also need to have stable background treatment for pulmonary arterial hypertension.
Study Locations (29 sites)
Xuanwu Hospital Capital Medical University, Beijing, Beijing Municipality China
The first hospital of Jilin University, Jilin City, Changchun China
The first hospital of Jilin University, Jilin City, Changchun China
Fujian Medical University Union Hospita, Fuzhou, Fujian China
Xiamen Hospital of T.C.M., Xiamen, Fujian China
Gansu Provincial Hospital, Lanzhou, Gansu China
Guangdong Provincial People's Hospital, Guangzhou, Guangdong China
Guangdong Provincial People's Hospital, Guangzhou, Guangdong China
The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou China
Fuwai Center China Cardiovascular Hospital, Zhengzhou, Henan China
Eligibility Criteria
Inclusion Criteria: 1. Participants aged 18-75 years old (inclusive), any gender; 2. Patients diagnosed with WHO Group 1 pulmonary arterial hypertension (PAH) via right heart catheterization (RHC) before dosing (see Appendix 1), including the following subtypes: * Idiopathic PAH; * Heritable PAH; * Drug- or toxin-induced PAH; * Inactive, connective tissue disease-associated PAH; * Simple congenital heart disease with left-to-right shunt-related PAH, at least 1 year post-repair surgery; 3. Symptomatic pulmonary arterial hypertension, WHO functional class II or III ; 4. Must also meet the following hemodynamic criteria: * Mean pulmonary arterial pressure (mPAP) at rest ≥25 mmHg; * Pulmonary arterial wedge pressure (PAWP) ≤15 mmHg; 5. Pulmonary vascular resistance (PVR) measured by RHC within 10 days before initial dosing ≥5 Wood Units (400 dyn·sec·cm-5), prior RHC results before screening are acceptable if they meet study requirements; 6. Receiving stable doses of background PAH therapy (i.e., for at least 90 days before first dosing, individualized target doses for each therapy reached and stable); for subcutaneous prostacyclin users, a 10% variation around the optimal dose is allowed following medical practice, detailed as follows: * Background PAH therapy refers to approved PAH-specific drugs, including ERA and/or PDE-5i or sGC stimulators and/or prostacyclin analogs or receptor agonists (subcutaneous). Note: PAH background therapy drugs should meet the following doses: Macitentan 10 mg qd, Ambrisentan 10 mg qd; Sildenafil ≥20 mg tid, Tadalafil 20-40 mg qd; Riociguat 2 mg or 2.5 mg tid; Selexipag 0.8-1.6 mg bid; Subcutaneous treprostinil ≥20 ng/kg/min. Note: Drugs used for acute pulmonary vasoreactivity testing are not considered background therapy. 7. During screening and within 10 days before first dosing, the mean of two 6-minute walk distance (6MWD) tests should be ≥150m and ≤450m, with a maximum difference of 15% (based on the higher value); the two tests should be at least 4 hours apart and no longer than 1 week apart (if the difference exceeds 15%, repeat once within 4 hours to 1 week). 8. Female participants of childbearing potential must have a negative serum pregnancy test before dosing, agree to regular urine or serum pregnancy tests during treatment (any one), use highly effective contraception before dosing, during treatment (including dosing interruption) and for 16 weeks (112 days) after the last dose, and avoid blood or egg donation for 16 weeks (112 days) after the last dose. 9. Male participants agree to use condoms, defined as using latex condoms or non-latex condoms made from non-natural (animal) membranes (e.g., polyurethane) during sexual activity with pregnant women or women of childbearing potential during the dosing period (including any interruption) and for 16 weeks (112 days) after the last dose, even if they have successfully undergone a vasectomy, and to avoid donating sperm during this time; 10. Participants understand and follow the study procedures, voluntarily participate, and sign the informed consent form. Exclusion Criteria: 1\) Diagnosed with WHO Group 2, 3, 4, or 5 pulmonary hypertension. 2) Diagnosed with the following PAH subtypes in WHO Group 1: * HIV-associated PAH * Portal hypertension-associated PAH * Schistosomiasis-associated PAH * PAH associated with pulmonary veno-occlusive disease or pulmonary capillary hemangiomatosis * PAH patients with known positive acute pulmonary vasoreactivity test 3) History of echocardiogram within 6 months before screening showing left ventricular ejection fraction \<45%, or pre-dose echocardiogram showing left ventricular ejection fraction \<45%, or as assessed by the investigator, acute decompensated heart failure occurring within 30 days before screening, or evidence or history of clinically significant heart disease (including but not limited to: significant (≥2+) mitral or aortic valve regurgitation, restrictive or congestive cardiomyopathy, or pericardial constriction). 4\) Poorly controlled hypertension at rest during the screening period: seated systolic BP \>160 mmHg or seated diastolic BP \>100 mmHg, or pre-dose systolic BP \<90 mmHg on Day 1. 5\) Pre-dose ECG Fridericia corrected QT interval (QTcF) ≥470 ms for men, ≥480 ms for women, or personal/family history of long QT syndrome (LQTS) or sudden cardiac death. 6\) Any symptomatic coronary artery disease event (previous myocardial infarction, PCI, CABG, or angina), or history of cerebrovascular accident within 3 months before screening. Note: if coronary angiography shows no obstruction (lumen stenosis ≤50%), angina may not be an exclusion. 7\) Use of IV positive inotropic agents (such as dobutamine, dopamine, norepinephrine, vasopressin, milrinone, levosimendan, etc.) within 30 days before the screening visit. 8\) History of arterial or deep vein thrombosis within 6 months before dosing, or any spontaneous bleeding of any severity within 2 months before dosing. 9\) Untreated mild or more severe obstructive sleep apnea history. 10)Previous or planned heart or lung transplant, or expected lifespan \<12 months as assessed by the investigator. 11\) Diagnosed with chronic obstructive pulmonary disease (COPD) or other clinically significant lung diseases. 12\) Exclusion if there is evidence of interstitial lung disease (ILD) from a chest CT within 1 year before screening or a lung function test (PET) within 6 months before screening; if these test results are not available, or if the chest CT within 1 year shows mild or more severe ILD, a lung function test (PET) or chest CT must be done during the screening period, and patients with ILD detected are excluded. 13\) Before administration, hemoglobin (Hb) \> the upper limit of normal (ULN) for their gender or \<90 g/L, platelet count ≤100×10⁹/L, neutrophils \<1.5×10⁹/L, AST or ALT \>3×ULN, total bilirubin \>1.5×ULN, estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73m² (defined according to CKD-EPI 2021 formula). 14\) History of portal hypertension or chronic liver disease, including positive Hepatitis B surface antigen (HBsAg) and/or positive Hepatitis B core antibody (HBcAb) with HBV-DNA levels above the normal range; positive Hepatitis C virus (HCV) and positive HCV-RNA; positive HIV serology; positive Treponema pallidum antibody (TP-Ab) (if Treponema pallidum serology is positive, a non-Treponema pallidum serology test should be done, and if negative and judged by the investigator as a cured past syphilis infection, the patient can be included). 15\) Currently participating in other clinical studies; or has participated in a medical device or drug clinical study within 30 days before screening (except those who only signed the ICF but did not receive investigational drug or device intervention), or still within 5 half-lives (t1/2) of an investigational product (whichever is longer). 16\) Previously received treatment targeting the TGF-β superfamily (e.g., Sotatercept), including participation in clinical trials. 17\) Known allergies to large molecule protein products/monoclonal antibodies, the study drug or its excipients, or drugs of the same type. 18\) Started a cardiopulmonary rehabilitation exercise program within 90 days before screening, or planning to start one during the study (participants who have maintained a stable program and will continue during the study are eligible). 19\) History of opportunistic infections (e.g., invasive candidiasis or Pneumocystis pneumonia within 6 months before dosing); severe local infections (e.g., cellulitis, abscess) or systemic infections (e.g., sepsis) within 4 weeks before screening. 20\) Major surgery within 8 weeks before the first dose, or participants not fully recovered from previous surgery before the first dose. 21\) If receiving corticosteroid therapy, any of the following within 30 days before the first dose: taken \>20
Conditions Breast Cancer, Radiation Therapy Patient
Phase NA
Enrollment 55
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this interventional study is to to evaluate the effectiveness and acceptability of a focused upper body massage when offered after radiation treatments to participants diagnosed with breast cancer. Given the prevalence of musculoskeletal complaints during radiation therapy delivery and acknowledging the emotional stress associated with breast cancer diagnosis and treatment, the aims of this pilot study are to: 1) evaluate the effectiveness of a focused upper body massage, available after radiation treatments, on patient's muscle and joint achiness and disability/symptoms of the upper extremities; 2) evaluate the effectiveness of a focused chair massage, available after radiation treatments on health-related quality of life; 3) assess the need for repeating the pre-radiation simulation process and revising the established treatment plan; and 4) and evaluate patient acceptability of the massages offered during the course of radiation treatment.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: upper body massage — brief massage of the upper back, neck, shoulders, arms, and hands; participant is fully clothed during the massage

Primary Outcomes

  • Musculoskeletal and Joint Pain (Measured: Baseline; Every 7 days up to 10 weeks; 6 weeks after participant study completion)
  • Disability of the Arm, Shoulder and Hand - short version (QuickDASH) (Measured: Baseline; Every 7 days up to 10 weeks; 6 weeks after participant study completion)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-01
Completion: 2027-08-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 55 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ohio State University Comprehensive Cancer Center
Principal Investigators:
  • Beth Steinber, PhD, RN (PRINCIPAL_INVESTIGATOR) - Ohio State University
  • Sachin Jhawar, MD (PRINCIPAL_INVESTIGATOR) - Ohio State University
Contact Information
Study Contact:
Beth Steinberg, PhD, RN
614-406-7067
beth.steinberg@osumc.edu
Sienna Andres, BA
380-283-6479
sienna.andres@osumc.edu
Beth Steinberg, PhD, RN
614-406-7067
beth.steinberg@osumc.edu
The Ohio State University
Interventions
  • Other: upper body massage — brief massage of the upper back, neck, shoulders, arms, and hands; participant is fully clothed during the massage
Study Locations (1 sites)
The Ohio State University, Columbus, Ohio 43210 United States
Eligibility Criteria
Inclusion Criteria: 1. 18 years of age or older 2. Diagnosis of breast cancer 3. Treatment plan for curative intent radiation at SSBC 4. Radiation treatment frequency can be daily, every other day, and twice weekly 5. Agreeable to and available for focused chair massages post-radiation treatments during the prescribed treatment period Exclusion Criteria: 1. Patients with recurrent disease (breast cancer) 2. Patients treated palliatively with radiation treatments 3. Inability to read and/or understand English (consent and questionnaires in English) 4. Patients with documented cognitive disorder that limits the ability to independently read, understand, and/or complete the survey measures; i.e. dementia, Alzheimer's 5. Patients with major psychiatric disorders not controlled by medication or other psychiatric treatments
Conditions Wound Care, Pain, Neuropsychiatric Sympt...
Phase NA
Enrollment 25
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will test whether immersive virtual reality (iVR) can reduce pain and discomfort during wound care for residents living in long-term care (LTC). Pressure ulcers are common and painful among older adults, and dressing changes often cause additional distress. Up to 20 residents at the Donald Berman Maimonides Geriatric Centre will use virtual reality headsets during routine wound care. The headsets display calm, low-stimulus scenes (e.g., puppies in a meadow) designed to distract and comfort participants. Each participant will take part for six weeks in three phases: * Two weeks of usual wound care (baseline) * Two weeks using virtual reality during wound care (intervention) * Two weeks of usual care again (washout) Pain will be assessed using validated tools, and the research team will also observe agitation, mood, and other behavioral indicators. Nursing staff will provide feedback on feasibility and acceptability of iVR use in LTC settings.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Crossover Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Device: Rendever Immersive Virtual Reality Platform — IVR headsets will provide calming, low-intensity scenes-like watching puppies in a meadow-to provide distraction and help reduce pain during wound care.

Primary Outcomes

  • Pain Assessment Checklist for Seniors with Limited Ability to Communicate (PACSLAC-II) (6 weeks)
  • Pain Assessment in Advanced Dementia (PAINAD) (6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-01
Completion: 2027-04-15
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 25 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: McGill University
Collaborators: Lady Davis Institute
Principal Investigators:
  • Machelle Wilchesky, PhD (PRINCIPAL_INVESTIGATOR) - Lady Davis Institute-CIUSSS du Centre-Ouest-de-l'Île-de-Montréal
Contact Information
Study Contact:
Machelle Wilchesky, PhD
(514) 340-8222
machelle.wilchesky@mcgill.ca
Stephanie A Ballard, MSc
(514) 483-2121
stephanie.ballard@mail.mcgill.ca
Ava ter Horst, BSc
(514) 483-2121
ava.terhorst.ccomtl@ssss.gouv.qc.ca
Donald Berman Maimonides Maimonides Geriatric Centre
Interventions
  • Device: Rendever Immersive Virtual Reality Platform — IVR headsets will provide calming, low-intensity scenes-like watching puppies in a meadow-to provide distraction and help reduce pain during wound care.
Study Locations (2 sites)
Donald Berman Maimonides Maimonides Geriatric Centre, Montreal, Quebec H4W 1W3 Canada
Donald Berman Maimonides Maimonides Geriatric Centre, Montreal, Quebec H4W 1W3 Canada
Eligibility Criteria
Inclusion Criteria: * Resident of LTC for ≥2 weeks * Receiving regular wound care for pressure ulcers * Able to tolerate iVR headset use * (If cognitively apt) able to understand English or French Exclusion Criteria: * Blindness, severe cataracts, or glaucoma * Allergies to synthetic plastics or headset materials * Head or ear wounds preventing headset placement * Peripheral neuropathy * Dangerous or aggressive behaviors in the past 30 days
Conditions Depresssion
Phase NA
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The research aims to investigate the effectiveness of playback theatre program on improving mental health for adolescents and youth. This study adopts a multicentre randomized control trial two arms research design. A randomised controlled trial will compare a typical 7-session therapeutic song-writing program with a waitlist-control group to determine whether the 7-session playback theatre program can produce better outcomes for young people with depressive symptoms, including improvement in depressive symptoms, self-stigma, self-esteem, sense of hope and social support at post-intervention. The 7-session playback theatre program will be delivered by trained and experienced social workers and helping professionals who are familiar with music therapy. A research staff, who does not involve in the group allocation and delivery of group intervention, conduct the intervention outcomes assessment of the participants before and after the intervention. Standardized assessment tools are used to assess the intervention outcomes. The ethical considerations of this study were reviewed and approved by the Human and Artefacts Ethics Sub-Committee of the City University of Hong Kong in 2026.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Playback theatre program — The playback theatre program consists of 7 sessions. One session will be conducted per week, with each session lasting for about 90 minutes. A social worker and a helping professional who is familiar with music therapy will be recruited to run the playback theatre program at a collaborative social service centre and school. A standardized program manual is designed by the research team. The social worker and a counsellor who run the playback theatre program will receive training and supervision on conducting the playback theatre program by the research team
  • Behavioral: Waitlist control group — Waitlist control group will receive will receive treatment as usual provided by the collaborative centres and schools, including recreational activities and interest classes, at the initial stage and will receive the same playback theatre program at a later stage

Primary Outcomes

  • The Chinese Depression Anxiety Stress Scale (DASS-Y) (It will be used before and after the intervention (over 7-weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-09-01
Completion: 2027-10-31
Eligibility
Age: 13 Years and older
Sex: ALL
Volunteers: true
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: City University of Hong Kong
Collaborators: The Salvation Army, Hong Kong and Macau Command
Contact Information
Study Contact:
Kim-wan Daniel Young, PhD
+852 34428954
dkwyoung@cityu.edu.hk
Young Daniel Kim-wan, PhD
+852 34428954
dkwyoung@cityu.edu.hk
City University of Hong Kong
Interventions
  • Behavioral: Playback theatre program — The playback theatre program consists of 7 sessions. One session will be conducted per week, with each session lasting for about 90 minutes. A social worker and a helping professional who is familiar with music therapy will be recruited to run the playback theatre program at a collaborative social service centre and school. A standardized program manual is designed by the research team. The social worker and a counsellor who run the playback theatre program will receive training and supervision on conducting the playback theatre program by the research team
  • Behavioral: Waitlist control group — Waitlist control group will receive will receive treatment as usual provided by the collaborative centres and schools, including recreational activities and interest classes, at the initial stage and will receive the same playback theatre program at a later stage
Study Locations (1 sites)
City University of Hong Kong, Kowloon Tong, Hong Kong Hong Kong
Eligibility Criteria
Inclusion Criteria: 1. aged between 13 to 24 years; 2. having mild to moderate depression and/or anxiety as assessed using a standardized assessment tool, i.e. Chinese Depression Anxiety Stress Scale-Youth (DASS-Y) with a DASS-Y Depression score between 5 and 12; 3. service users of The Salvation Army social service unit; and 4. giving informed consent to this research work. For those aged below 18, parental consent will be obtained. Exclusion Criteria: 1. Having severe depression (i.e. a DASS-Y Depression score ≥ 13); 2. Having severe anxiety (i.e. a DASS-Y Anxiety score ≥ 8); and 3. Having suicidal risk
Conditions Solid Tumor, Small Cell Lung Cancer (SCL...
Phase PHASE1
Enrollment 40
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: EXS74539 — Oral administration

Primary Outcomes

  • Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) (Up to 3 years)
  • Number of Participants with Dose-limiting Toxicity (DLT) (Up to 28 days)
  • Number of Participants with Dose Interruptions and Dose Modifications (Up to 3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-04-13
Completion: 2029-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Contact Information
Study Contact:
Exscientia AI Ltd.
385-374-1724
clinicaltrials@recursion.com
Interventions
  • Drug: EXS74539 — Oral administration
Study Locations (3 sites)
Start Lacn, Los Angeles, California 90025 United States
START Dallas, Fort Worth, Texas 76104 United States
START Mountain Region, West Valley City, Utah 84119 United States
Eligibility Criteria
Key Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. * Histologically confirmed diagnosis of the following solid tumors: * SCLC * High grade neuroendocrine or small cell carcinomas of non-lung origin * Non-small cell lung cancer \[NSCLC\] * Prostate cancer * Ovarian cancer * Renal carcinoma \[clear and non-clear cell\] * Head and neck squamous cell carcinoma * Hepatic cancer * Gastric cancer * Triple-negative breast cancer \[TNBC\] * Participant disease should have progressed, relapsed or the participants should have been intolerant to at least one prior standard systemic therapy for their respective underlying malignancy. * Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Key Exclusion Criteria: * Any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the participant's safety or ability to participate in the study. * Symptomatic brain metastases, leptomeningeal metastases, or spinal cord compression due to disease. Participants with brain metastases must be clinically stable and off corticosteroids and anticonvulsants for ≥1 month prior to study treatment and not require any specific intervention for brain metastases. * Active and clinically significant infection requiring systemic antibacterial, antiviral, or antifungal therapy \<7 days of the first scheduled dose of the study treatment. * Significant cardiac abnormalities. * Major surgery within 28 days prior to the start of study treatment. Note: Other protocol-defined inclusion and exclusion criteria may apply.
Conditions Type 2 Diabetes Mellitus
Phase NA
Enrollment 350
Locations 27 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

A multi-center, 26-week randomized controlled trial (RCT) to evaluate the safety and efficacy of the fully closed loop Omnipod M System in adults with type 2 diabetes using basal/bolus insulin therapy or basal-only insulin therapy, with the primary endpoint after 15 weeks and secondary analysis at 26 weeks; followed by an extension phase after completion of the 26-week trial where the Intervention group will continue to use Omnipod M and the Control group will crossover to use Omnipod M for 26 weeks

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Device: Omnipod M System with study CGM — The Omnipod M system with the study CGM
  • Device: Standard Therapy plus study CGM — Standard therapy is continuation of pre-study insulin regimen and study CGM.

Primary Outcomes

  • HbA1c (15 and 26 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-30
Completion: 2027-09-23
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 350 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Insulet Corporation
Collaborators: Jaeb Center for Health Research
Contact Information
Study Contact:
Trang Ly, MBBS, PhD
978-600-7000
APClinical@insulet.com
Bonnie Dumais, RN
978-600-7000
APClinical@insulet.com
Martha Walker
323-362-1322
mawalker@usc.edu
University of Southern California
Interventions
  • Device: Device: Omnipod M System with study CGM — The Omnipod M system with the study CGM
  • Device: Standard Therapy plus study CGM — Standard therapy is continuation of pre-study insulin regimen and study CGM.
Study Locations (27 sites)
University of Southern California, Los Angeles, California 90022 United States
HOAG, Newport Beach, California 92663 United States
Sansum Diabetes Research Institute, Santa Barbara, California 93105 United States
Touro University California, Vallejo, California 94592 United States
University of Colorado Denver, Denver, Colorado 80204 United States
University of South Florida, Tampa, Florida 33612 United States
Metabolic Research Institute, West Palm Beach, Florida 33401 United States
EMORY, Atlanta, Georgia 30308 United States
Atlanta Diabetes Associates, Atlanta, Georgia 30318 United States
Endocrine Research Solutions, Inc., Rosewell, Georgia 30076 United States
Eligibility Criteria
Inclusion Criteria: 1. Age at time of consent 18-75 years (inclusive) 2. Clinical diagnosis, based on investigator assessment, of type 2 diabetes for at least 6 months at time of screening 3. On insulin therapy for at least 3 months at time of screening, with no change to insulin regimen for 6 weeks prior (AID use within past 3 months excluded) to initiating baseline CGM data collection. * Regimen is defined as (1) Basal-bolus insulin therapy (a) using multiple daily injections of insulin (MDI), (b) non-automated insulin pump, or (c) MDI with premix insulin; or (2) basal insulin only (without bolus insulin). * Basal-bolus insulin therapy defined as use of a basal insulin (either long-acting or intermediate-acting (e.g., NPH) plus at least one mealtime insulin dose per day, or a non-automated insulin pump * Inhaled insulin may be used in addition to or instead of mealtime injections pre-study and as part of the Control group 4. For basal only users, screening A1C ≥7.5% and \<14.0%. For basal bolus users (i.e., all others), screening A1C ≥6.0% and \<14.0%. • A1C measurement within 28 days prior to enrollment is acceptable 5. Willing to use only the following types of U-100 insulin while using the study pump: Humalog, Novolog, Admelog, Kirsty, Fiasp, Lyumjev or their generic/biosimilar equivalents 6. Willing to use only study-provided Libre 2 Plus or 3 Plus sensor during the study and not use another sensor 7. Deemed appropriate for pump therapy per Investigator's assessment considering previous history of severe hypoglycemic and hyperglycemic events, and other comorbidities 8. No anticipated need to newly initiate noninsulin glucose-lowering medications (such as GLP-1 receptor agonist, SGLT2 inhibitor, or other) or weight-reduction medications that have a glucose lowering effect during the 26-week RCT phase. (Additions or changes in these medications will be permitted during the Extension Phase) 9. If using noninsulin glucose-lowering medications (such as GLP-1 receptor agonist, SGLT2 inhibitor, or other) or weight-reduction medications that have a glucose-lowering effect, prescribed dose has been stable for 6 weeks prior to baseline CGM collection; and there is not an anticipated need to increase the dose during the 26-week trial phase (dose reductions will be permitted for safety). 10. Investigator has confidence that the participant can safely operate all study devices and can adhere to the protocol 11. Willing to wear the system, including Pods, continuously throughout the 26-week trial phase 12. Willing and able to sign the Informed Consent Form (ICF) 13. Able to read and understand English 14. If of childbearing potential, willing and able to have pregnancy testing Exclusion Criteria: 1. Use of an automated insulin delivery pump within 3 months prior to screening 2. Any medical condition, which in the opinion of the Investigator, would put the participant at an unacceptable safety risk. This may include untreated malignancy, unstable cardiac disease, unstable or end-stage renal disease, unstable proliferative retinopathy, unstable psychiatric conditions such as eating disorders, drug or alcohol abuse. 3. Current or known history of coronary artery disease that is not stable with medical management in the opinion of the investigator, including unstable angina, despite medical management, or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the 12 months prior to screening 4. Any planned surgery during the study which could be considered major in the opinion of the Investigator 5. History of more than 1 episode of severe hypoglycemia in the past 6 months. Severe hypoglycemia is defined as an event that requires the assistance of another person due to altered consciousness, and requires another person to actively administer carbohydrate, glucagon, or other resuscitative actions. 6. History of more than 1 episode of diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS) in the past 6 months, unrelated to an intercurrent illness; kinked, dislodged, or occluded cannula; or initial diabetes diagnosis 7. Unable to tolerate adhesive tape or has any unresolved skin condition that could impact sensor or pump placement 8. Blood disorder or dyscrasia within 3 months prior to screening, which in the Investigator's opinion could interfere with determination of HbA1c 9. Plans to receive blood transfusion over the course of the 26-week trial phase. 10. Pregnant or lactating, or is of childbearing potential and not using an acceptable form of birth control (acceptable forms of contraception include abstinence, barrier methods such as condoms, hormonal contraceptives, intrauterine device, surgical sterilization such as tubal ligation or hysterectomy, or vasectomized partner); childbearing potential means that menstruation has started, and the participant is not surgically sterile or greater than 12 months post-menopausal). 11. Has taken systemic corticosteroids (oral or injectable) within 4 weeks or has had a local steroid injection (intraarticular, epidural) within 1 week prior to baseline CGM collection or plans to take oral or injectable steroids during the 26-week trial phase. 12. Participation in another clinical study using an investigational drug or device within prior 30 days or intends to participate in any other interventional study during the 26-week trial phase 13. Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the Investigator's clinical judgment 14. Participant is an employee of Insulet, an Investigator or a member of Investigator's study team, or immediate family member of any of the aforementioned
Conditions Vulvar Adenocarcinoma, PDAC - Pancreatic...
Phase PHASE1
Enrollment 174
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a first-in-human (FIH), Phase 1 open-label, multicenter dose escalation study investigating AVA6103 monotherapy administered intravenously in patients with locally advanced (unresectable) or metastatic solid tumors that are likely to be FAP positive. The study consists of an initial Phase 1a dose escalation portion and a subsequent Phase 1b dose expansion portion upon completion of the dose escalation portion.

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: AVA6103 — AVA6103 is a FAP-activated Exatecan

Primary Outcomes

  • Adverse events (AEs) (From Day 1 until up to 30 days after last dose of study drug.)
  • Dose-limiting toxicities (DLTs) (21 days from the first dose for the every 3 week dosing schedule and 28 days from the first dose for the every 2 week schedule)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-03-31
Completion: 2030-06
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 174 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Avacta Life Sciences Ltd
Contact Information
Study Contact:
Avacta Clinical Team
+44 (0)20 3911 0353
clinicaltrials@avacta.com
Ronan Pleass
ronan.pleass@startresearch.com
START Midwest
Mofopefoluwa Akinwale
(972) 893-8800
fakinwale@nextoncology.com
NEXT Oncology
Interventions
  • Drug: AVA6103 — AVA6103 is a FAP-activated Exatecan
Study Locations (3 sites)
START Midwest, Grand Rapids, Michigan 49546 United States
NEXT Oncology, Irving, Texas 75039 United States
NEXT Oncology Virginia, Fairfax, Virginia 22031 United States
Eligibility Criteria
Inclusion Criteria: 1. The subject is fully informed about the study and is willing and able to sign the informed consent form (ICF). 2. Male or female subjects, ≥18 years of age. 3. Subjects with the following tumors reported to be FAP positive, with histological or cytological confirmation of a locally advanced (unresectable) and/or metastatic progressing disease that have received all standard-of-care or Food and Drug Administration (FDA) approved treatments, or are ineligible for those treatments, or decline those treatments 1. Cervical/vulvar cancer 2. SCLC 3. Gastric/GEJ cancer 4. PDAC 5. CRC 6. HR+ breast cancer 4. Has a life expectancy of ≥3 months, in the opinion of the investigator. 5. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 6. Has recovered from all acute toxic effects of any prior radiotherapy, chemotherapy, or surgical procedure (must have resolved to CTCAE Grade ≤1 or returned to baseline, whichever is greater. Exceptions include alopecia and peripheral neuropathy, which can be up to CTCAE Grade 2). 7. Has adequate hematological function (applies only to subjects not receiving therapeutic anticoagulation; subjects receiving therapeutic anticoagulation should be on a stable dose): 1. Absolute neutrophil count of ≥1.5 × 109 cells/L. Subjects with documented benign ethnic neutropenia may be enrolled with an absolute neutrophil count of ≥1.0 × 109 cells/L 2. Hemoglobin ≥9.0 g/dL. 3. Platelet count of ≥100,000/µL. 4. International normalized ratio and activated partial thromboplastin time ≤1.5 times the ULN, except for subjects on direct acting anticoagulation. 8. Has adequate liver function: 1. Total bilirubin 1.5 × ULN (except for subjects with documented Gilbert's Syndrome or liver metastases who must have a total bilirubin \<3 × ULN). 2. AST and ALT ≤2.5 × ULN (in subjects with liver metastases, \<5 × ULN is allowed). 9. Has adequate renal function as defined by creatinine clearance ≥ 60 mL/min by the Cockcroft-Gault equation. 10. Women of childbearing potential and women who have ≤2 years amenorrhea after start of menopause, must have a negative serum or urine pregnancy test within 7 days prior to Cycle 1 Day 1. 11. Contraception requirements: 1. Female subjects of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or use a highly effective contraceptive method (Pearl Index failure rate \< 1% per year) during the treatment period and for at least 6 months after the last dose of study drug. 2. Male subjects with female partners of childbearing potential must agree to using 2 acceptable methods of contraception (Pearl Index failure rate \<1% per year), including a barrier method (with or without spermicide) during the treatment period and for at least 6 months after the last dose of study drug. 3. Male subjects must agree to refrain from sperm donation during the treatment period and for at least 6 months after the last dose of study drug. 12. The subject is willing and able to comply with the protocol, including any PK blood sampling and tumor biopsy requirements and agrees to return to clinic for follow-up visits and examinations. 1. For subjects in Phase 1a or 1b, on treatment tumor biopsy is optional. - Exclusion Criteria: 1. Has active or suspected central nervous system (CNS) metastases as determined by the Investigator. Subjects may still be eligible if CNS metastases are definitively treated with radiotherapy, the subject is asymptomatic, not requiring corticosteroids (prednisone or equivalent must be 10 mg/day or less), and have had repeat imaging no less than 4 weeks after completing radiotherapy to document stability. 2. Subjects who have any history of an active (requiring treatment) other malignancy (except any in-situ carcinoma, non-melanoma skin carcinoma and early prostate cancer with a normal prostate-specific antigen) within 2 years of study entry. 3. Has a significant, uncontrolled, concomitant disease that could affect compliance with the protocol. 4. History or evidence of any other clinically unstable/uncontrolled disorder, condition, or disease (including, but not limited to, cardiopulmonary, renal, metabolic, hematologic or psychiatric) other than their primary malignancy, that in the opinion of the Investigator would pose a risk to subject safety or interfere with study evaluations, procedures, or completion. 5. History of known infection is defined as: 1. HIV infection defined as: An AIDS-defining infection within 12 months of planned study Day 1. Subjects on anti-retroviral treatment who are not established on anti-retroviral treatment for ≥4 weeks and who have a viral load \>400 copies/mL prior to study Day 1. 2. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection defined as: a positive hepatitis B surface antigen (HBsAG) test at screening. Subjects with a past or resolved HBV infection (defined as having a negative HBsAG test and a positive antibody to hepatitis B core antigen antibody test) are eligible. Subjects positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA. 3. Chronic HBV (HBsAg positive, undetectable or low HBV DNA and normal ALT). 4. Subjects with active disease who are not on/have not initiated anti-retroviral treatment prior to study Day 1. 5. Subjects with untreated HCV infection or have not completed treatment for HCV infection. 6. Subjects with treated HCV infection but with an HCV viral load above the level of quantification. 7. Has a severe infection (requiring IV antibiotic treatment) within 21 days prior to Cycle 1, Day 1 including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia. 6. Has any other clinically significant active disease, metabolic dysfunction, physical examination finding, altered mental status, clinical laboratory finding, or reasonable suspicion of a disease or condition that would contraindicate the use of an investigational drug in the opinion of the investigator. 7. Has had major surgery within 21 days prior to Cycle 1, Day 1 (excluding biopsies) or anticipates the need for major surgery during study treatment. 8. Is a pregnant or breastfeeding woman. 9. Has a known hypersensitivity to any of the components of AVA6103 or any excipient of the product or to other topoisomerase 1 (TOP1) inhibitors. 10. Has received prior investigational therapy (defined as a treatment for which there is no Regulatory Authority-approved indication) within 5 half-lives or 28 days (whichever is shorter) of Cycle 1 Day 1. 11. Has received any approved anticancer therapy, including chemotherapy or hormonal therapy, within 14 days (or 5 half-lives, whichever is shorter) prior to Cycle 1 Day 1, with the following exception: 1. Is planned for on-study treatment or has received within 14 days (or 5 half-lives, whichever is shorter) prior to Cycle 1 Day 1. 2. Subjects who have received a monoclonal antibody. 12. Is currently taking St John's Wort, any drugs that are a strong inhibitor or inducer of cytochrome P450 (CYP)3A4, CYP1A2, CYP2D6, or P-glycoprotein (P-gp) such as ketoconazole, Nifedipine, erythromycin and fentanyl. 13. Drugs which are strong inhibitors of multidrug resistance protein (MRP)2, MRP3 or MRP4. 14. Is planned for on study treatment with any drugs that are sensitive CYP3A4 or organic anion transporting polypeptide (OATP)1B3 substrates, and/or where these drugs will be in the systemic circulation at the start of Cycle 1, Day 1. For this protocol, it means that the drug must not be used within 5 half-lives (or 5 days, whichever is longer) prior to AVA6103 Cycle 1 Day 1 and during study treatment. 15. Has received granulocyte-colony stimulating factor (G-CSF), or red blood cell or platelet transfusion within 14 days prior to Cycle 1 Day 1. 16. Has received radiotherapy within 28 days prior to Cycle 1 D
Conditions Obesity, Type 2 Diabetes
Phase PHASE3
Enrollment 2500
Locations 303 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive either CagriSema or semaglutide, and which treatment participants receive is decided by chance. CagriSema is a new study medicine being tested, while semaglutide is a medicine that doctors can already prescribe. The study will last for about 83 weeks

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Cagrisema — Cagrisema (Cagrilintide and Semaglutide) will be administered subcutaneously.
  • Drug: Semaglutide — Semaglutide will be administered subcutaneously.

Primary Outcomes

  • Relative change in body weight (From randomisation (week 0) to end of treatment (week 72))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-05-21
Completion: 2028-04-19
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 2500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Novo Nordisk A/S
Principal Investigators:
  • Clinical Transparency (dept. 2834) (STUDY_DIRECTOR) - Novo Nordisk A/S
Contact Information
Study Contact:
Novo Nordisk
(+1) 866-867-7178
clinicaltrials@novonordisk.com
Interventions
  • Drug: Cagrisema — Cagrisema (Cagrilintide and Semaglutide) will be administered subcutaneously.
  • Drug: Semaglutide — Semaglutide will be administered subcutaneously.
Study Locations (303 sites)
Uni of Alabama at Birmingham, Birmingham, Alabama 35294 United States
Cahaba Research, Pelham, Alabama 35124 United States
Elligo Health Research Inc, Gilbert, Arizona 85296 United States
Velocity Clinical Research-Phoenix, Phoenix, Arizona 85006 United States
Arkansas Clinical Research, Little Rock, Arkansas 72205 United States
Woodland Int. Research Group, Little Rock, Arkansas 72211 United States
Headlands Research California, LLC, Escondido, California 92025 United States
Neighborhood Healthcare, Escondido, California 92025 United States
Diabetes & Endocrine Specialists - La Mesa, La Mesa, California 91942 United States
Clinical Trials Research_Sacramento, Lincoln, California 95648 United States
Eligibility Criteria
Inclusion Criteria : * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18 years or above at the time of signing the informed consent. * BMI≥ 35.0 kg/m\^2. * Participants without T2D: No history of T2D and HbA1c \< 6.5% (48 millimoles per mole (mmol/mol)) Participants with T2D: A history of T2D and HbA1c \< 10% (\< 86 mmol/mol). If a participant without a history of diabetes during the screening period receives an HbA1c result of 6.5% (48 mmol/mol) or higher, the investigator or the participant's healthcare provider must confirm the diagnosis of type 2 diabetes before the participant is randomised. Exclusion Criteria: * A self-reported change in body weight \> 5% within 90 days before screening, irrespective of medical records. * Use of any glucagon-like-peptide-1 receptor agonist (GLP-1 RA), including medication with GLP-1 RA activity, or amylin analogues, including medication with amylin activity, within 6 months before screening.
Conditions Major Depression
Phase EARLY_PHASE1
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Many people with depression do not get better with standard treatments like medication. One promising alternative is transcranial magnetic stimulation (TMS), a non-invasive procedure that uses magnetic pulses to stimulate specific brain regions. A particular pattern of TMS called continuous theta-burst stimulation (cTBS) is thought to reduce overactive brain activity in depression, but the investigators do not yet fully understand how it works at the level of brain cells and connections. This study aims to determine the biological mechanism by which cTBS changes brain activity in people with depression. Specifically, the investigators are testing two competing ideas: (1) that cTBS works by weakening the connections between brain cells through a process called long-term depression (LTD), which is driven by a chemical messenger system called glutamate; or (2) that cTBS works by increasing the brain's natural "braking" system, driven by a different chemical messenger called GABA. To test these ideas, participants with depression will receive cTBS along with one of four FDA-approved medications, or placebo, that either boost or block these chemical messenger systems. The investigators will measure changes in brain activity using electroencephalography (EEG) recorded simultaneously with TMS. Specific patterns in the EEG signal, called TMS-evoked potentials (TEPs), act as a window into how different brain cell types are responding to stimulation. Each participant will complete four study visits, each testing a different drug-TMS combination in random order. One group of participants will test drugs targeting the glutamate system (d-cycloserine and memantine). A second group will test drugs targeting the GABA system (lorazepam and baclofen). All drugs are given as a single oral dose and are commonly used in clinical practice. Understanding exactly how cTBS works at a biological level could open the door to more effective, personalized TMS treatments.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Randomized Intervention model: Crossover Primary purpose: Basic Science Masking/blinding: Triple

Interventions / Regimen

  • Drug: D-Cycloserine (DCS) — D-cycloserine 100 mg is administered as a single oral dose approximately two hours prior to cTBS, timed to peak plasma concentration. At this dose, DCS acts as a partial agonist at the glycine co-agonist site of the NMDA receptor, facilitating NMDAR-mediated synaptic transmission. It is used in Aim 1 to test whether NMDAR agonism enhances cTBS-induced LTD-like plasticity at the dlPFC.
  • Device: Continuous theta-burst stimulation (cTBS) — Continuous theta-burst stimulation is delivered using the Nexstim NBS-6 system with integrated real-time neuronavigation. The cTBS protocol consists of 600 pulses delivered at 80% active motor threshold, targeting the left dorsolateral prefrontal cortex (dlPFC) localized to individual structural MRI.
  • Device: Transcranial Magnetic Stimulation Sham — Sham TMS is delivered using an identical coil that produces the same auditory and somatosensory scalp sensation as active stimulation without inducing a significant cortical response. The stimulation protocol will be the same as the active cTBS protocol.
  • Drug: Memantine — Memantine 10 mg is administered as a single oral dose approximately two hours prior to cTBS. Memantine is a non-competitive NMDA receptor antagonist acting at the phencyclidine site within the receptor channel. It is used in Aim 1 to test whether NMDAR antagonism blocks cTBS-induced LTD-like plasticity at the dlPFC.
  • Drug: Lorazepam (drug) — Lorazepam 1 mg is administered as a single oral dose approximately two hours prior to cTBS, timed to peak plasma concentration. Lorazepam is a positive allosteric modulator at GABA-A receptors, increasing chloride influx and membrane hyperpolarization. It is used in Aim 2 to test whether GABA-A receptor potentiation enhances cTBS-induced inhibition at the dlPFC.
  • Drug: Baclofen — Baclofen 50 mg is administered as a single oral dose approximately one hour prior to cTBS, timed to peak plasma concentration. Baclofen is a GABA-B receptor agonist that suppresses presynaptic neurotransmitter release from both GABAergic interneurons and glutamatergic neurons. It is used in Aim 2 to test whether GABA-B receptor agonism enhances cTBS-induced inhibition at the dlPFC.
  • Drug: Placebo — Sucrose packaged in identical cellulose capsules, administered orally.

Primary Outcomes

  • Change in P30 TEP Peak Amplitude (Measured at 4 timepoints within each study visit: pre-drug baseline, approximately 2 hours post-drug administration (immediately prior to cTBS), and approximately 5 and 20 minutes post-cTBS. Visits separated by at least 1 week.)
  • Change in N45 TEP Peak Amplitude (Measured at 4 timepoints within each study visit: pre-drug baseline, approximately 2 hours post-drug administration (immediately prior to cTBS), and approximately 5 and 20 minutes post-cTBS.)
  • Change in N100 TEP Peak Amplitude (Measured at 4 timepoints within each study visit: pre-drug baseline, approximately 2 hours post-drug administration (immediately prior to cTBS), and approximately 5 and 20 minutes post-cTBS.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2026-03-11
Completion: 2030-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mclean Hospital
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Joshua C Brown, MD, PhD (PRINCIPAL_INVESTIGATOR) - Mclean Hospital
Contact Information
Study Contact:
Prem Ganesh, MS
617-855-2153
pganesh@mgb.org
Dennis W Guevara
617-855-2340
dguevara@mclean.harvard.edu
Dennis W Guevara
617-855-2340
dguevara@mclean.harvard.edu
McLean Hospital
Interventions
  • Drug: D-Cycloserine (DCS) — D-cycloserine 100 mg is administered as a single oral dose approximately two hours prior to cTBS, timed to peak plasma concentration. At this dose, DCS acts as a partial agonist at the glycine co-agonist site of the NMDA receptor, facilitating NMDAR-mediated synaptic transmission. It is used in Aim 1 to test whether NMDAR agonism enhances cTBS-induced LTD-like plasticity at the dlPFC.
  • Device: Continuous theta-burst stimulation (cTBS) — Continuous theta-burst stimulation is delivered using the Nexstim NBS-6 system with integrated real-time neuronavigation. The cTBS protocol consists of 600 pulses delivered at 80% active motor threshold, targeting the left dorsolateral prefrontal cortex (dlPFC) localized to individual structural MRI.
  • Device: Transcranial Magnetic Stimulation Sham — Sham TMS is delivered using an identical coil that produces the same auditory and somatosensory scalp sensation as active stimulation without inducing a significant cortical response. The stimulation protocol will be the same as the active cTBS protocol.
  • Drug: Memantine — Memantine 10 mg is administered as a single oral dose approximately two hours prior to cTBS. Memantine is a non-competitive NMDA receptor antagonist acting at the phencyclidine site within the receptor channel. It is used in Aim 1 to test whether NMDAR antagonism blocks cTBS-induced LTD-like plasticity at the dlPFC.
  • Drug: Lorazepam (drug) — Lorazepam 1 mg is administered as a single oral dose approximately two hours prior to cTBS, timed to peak plasma concentration. Lorazepam is a positive allosteric modulator at GABA-A receptors, increasing chloride influx and membrane hyperpolarization. It is used in Aim 2 to test whether GABA-A receptor potentiation enhances cTBS-induced inhibition at the dlPFC.
Study Locations (1 sites)
McLean Hospital, Belmont, Massachusetts 02478 United States
Eligibility Criteria
Inclusion Criteria: * Can safely receive TMS and study drugs * Stable medication regimen for one month prior to study participation, and for the duration of the study * Not currently receiving TMS, ECT, or ketamine * No active safety concerns related to suicidality * Moderate to severe Major Depressive Disorder as indicated by the Patient Health Questionnaire or Quick Inventory of Depressive Symptomatology Exclusion Criteria: * History of seizures or epilepsy * History of intracranial pathology or lesions from any etiology * History of traumatic brain injury including prolonged loss of consciousness more than 15 min * Signs of increased intracranial pressure * Any major neurological conditions (ex: recent stroke, tumor, neurodegenerative disorders, etc.) * Major medical conditions that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.) * Severe migraines that may result in treatment intolerance. * Inability to tolerate MRI. * Pregnancy * Known allergic reaction to d-cycloserine, baclofen, memantine, or lorazepam
Conditions TNBC, Triple Negative Breast Cancer
Phase PHASE2
Enrollment 18
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to test whether a "rescue" strategy can turn chemotherapy-resistant triple-negative breast cancer (TNBC) into a curable state. Patients whose tumors fail to shrink after 2 cycles of standard neoadjuvant chemotherapy will receive a short, high-precision course of stereotactic body radiotherapy (SBRT, 24 Gy in 3 daily fractions) to the breast primary tumor, followed by 4 cycles of toripalimab (an anti-PD-1 antibody) combined with albumin-bound paclitaxel plus carboplatin. The main questions are: Can this SBRT-immuno-chemo triplet raise the pathologic complete response (pCR; no invasive cancer in breast or nodes at surgery)? Can it produce an objective radiologic response (ORR) in at least half of the patients, allowing more breast-conserving operations and fewer mastectomies? Secondary objectives include safety, changes in tumor-infiltrating lymphocytes (TILs), event-free survival, and exploratory biomarkers (whole-exome and RNA-seq, PBMC immunoprofiling) to discover signatures of benefit. Participants will undergo image-guided core biopsies before and after SBRT, provide serial blood samples, and have definitive surgery 3-5 weeks after the last cycle.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: SBRT — 24 Gy in 3 daily fractions (8 Gy each) to the breast primary tumor, started within 1 week after confirmation of chemotherapy resistance.
  • Drug: Toripalimab (anti-PD-1 antibody) — 240 mg intravenous infusion every 21 days for 4 cycles
  • Drug: Chemotherapy switch — Albumin-bound paclitaxel 125 mg/m² (days 1 \& 8) plus carboplatin AUC 6 (day 1)

Primary Outcomes

  • pCR rate (At definitive surgery, 3-5 weeks after completion of cycle 4 (week 15 from study entry))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-01-04
Completion: 2029-01-04
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 18 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
Contact Information
Study Contact:
Ting Zhang, phD.
+86-571-87783521
zezht@zju.edu.cn
Interventions
  • Radiation: SBRT — 24 Gy in 3 daily fractions (8 Gy each) to the breast primary tumor, started within 1 week after confirmation of chemotherapy resistance.
  • Drug: Toripalimab (anti-PD-1 antibody) — 240 mg intravenous infusion every 21 days for 4 cycles
  • Drug: Chemotherapy switch — Albumin-bound paclitaxel 125 mg/m² (days 1 \& 8) plus carboplatin AUC 6 (day 1)
Study Locations (1 sites)
The Department of Radiation Oncology,the Second Affiliated Hospital of Zhejiang University School of Medicine, hangzhou, zhejiang, Hangzhou, China
Eligibility Criteria
Inclusion Criteria: * Female, age 18-75 years, newly diagnosed invasive breast cancer. * Histologically confirmed triple-negative phenotype: ER \< 1 %, PR \< 1 % by IHC, HER2 negative (IHC 0/1+ or IHC 2+ with ISH negative). * Clinical stage II-III (T2-4 or N1-3, M0). * Completed 2 cycles of standard neoadjuvant chemotherapy (taxane ± anthracycline ± platinum) and assessed as non-responder: stable disease (SD) or progressive disease (PD) by RECIST 1.1. * ECOG performance status 0 or 1. * Radiation oncologist confirms suitability for SBRT and subsequent standard post-operative radiotherapy. * Adequate organ function within 14 days before enrollment: WBC ≥ 2 000/µL, ANC ≥ 1 500/µL, platelets ≥ 100 000/µL, Hb ≥ 9 g/dL; Serum creatinine ≤ 2 mg/dL or GFR ≥ 40 mL/min; AST/ALT ≤ 2.5 × ULN, total bilirubin ≤ ULN (≤ 3 mg/dL if Gilbert syndrome); INR ≤ 1.5 (on anticoagulation allowed if therapeutic range) * Negative HIV, HBV surface antigen, and HCV antibody (or HBV DNA / HCV RNA negative if false-positive). Exclusion Criteria: * Inflammatory breast cancer. * Any other malignancy requiring treatment within the past 3 years (except adequately treated basal-cell skin carcinoma or cervical CIS). * Active autoimmune disease, immunodeficiency, or systemic steroids \> 10 mg/day prednisone equivalent within 2 years. * Clinically significant cardiovascular disease (unstable angina, NYHA III/IV heart failure, recent MI). * Prior radiotherapy to the breast or chest wall. * Active infection requiring systemic therapy. * Known intolerance or hypersensitivity to toripalimab, paclitaxel, or carboplatin. * Pregnant or lactating women.